TransThera Sciences (Nanjing), Inc. (HKG:2617)
Hong Kong · Delayed Price · Currency is HKD 31.80
+0.10 (0.32%)
Jul 16, 2025, 4:08 PM HKT
TransThera Sciences (Nanjing) Company Description
TransThera Sciences (Nanjing), Inc., clinical stage biopharmaceutical company, discovers, develops, and commercializes small molecule therapies for oncology, inflammatory, and cardiometabolic diseases.
The company provides Tinengotinib (TT-00420), a MTK inhibitor for the treatment of drug-resistant, relapsed, or refractory cancers.
It also develops a pipeline of clinical stage product candidates and a preclinical stage product candidate.
TransThera Sciences (Nanjing), Inc. was formerly known as Nanjing TransThera Biosciences Co. Ltd. and changed its name to TransThera Sciences (Nanjing), Inc. in July 2021.
The company was incorporated in 2014 and is headquartered in Nanjing, China.
TransThera Sciences (Nanjing), Inc.
| Country | China |
| Founded | 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Frank Yongqian Wu |
Contact Details
Address: Building 9, Accelerator Phase 2 Nanjing, 210032 China | |
| Phone | 86 25 5821 6200 |
| Website | transtherabio.com |
Stock Details
| Ticker Symbol | 2617 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE100006T02 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Frank Yongqian Wu Ph.D. | Founder, Chief Executive Officer and Chairman |
| Di Wu | Vice President, Financial Controller and Executive Director |
| Songxi Cui | Vice President of Operations |
| Dr. Jing Fan | Chief Medical Officer |
| Jie Feng | Joint Company Secretary |
| Tik Wong CPA | Joint Company Secretary |